Drug intelligence / Profile preview

CYT-538

Development stage: Preclinical
Lead developer: Cytovia
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

CYT-538 is a drug candidate being developed by Cytovia Therapeutics in collaboration with Inserm. It is an NK cell-based therapy designed to target CD38 for the treatment of multiple myeloma, an incurable cancer. The development leverages Inserm's patented CD38 antibody and Chimeric Antigen Receptor (CAR) technology, which Cytovia combines with its proprietary induced pluripotent stem cell (iPSC) CAR NK and NK engager bispecific antibody platforms. This approach aims to provide a safer alternative to CAR-T therapies by utilizing the selectivity of the CD38 antibody and the potential of NK cells.

Beyond the preview

Go deeper on CYT-538.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYT-538.

Explore the full profile